首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1386214

全球白血病治療市場：趨勢、預測與競爭分析（~2030 年）

Leukemia Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2023年10月03日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

白血病治療趨勢和預測

預計到2030年，全球白血病治療市場規模將達到約214.6億美元，2024年至2030年年複合成長率為8.4%。該市場的主要促進因素是白血病盛行率的增加、對更有效的白血病治療的需求不斷增加以及醫療保健行業的研發費用增加。全球白血病治療市場前景廣闊，醫院藥局、藥局和零售藥局以及線上供應商市場都有商機。

白血病治療市場洞察

Lucintel 預測，由於慢性淋巴性白血病慢性淋巴性白血病的產品核可增加以及針對慢性淋巴性白血病的白血病治療方法的存在，慢性淋巴細胞白血病在預測期內仍將是最大的細分市場。

由於大眾對白血病及其治療方案的認知不斷提高，以及尋求醫院治療的人數增加，醫院藥局將繼續成為該市場的最大細分市場。

由於白血病治療再生醫學領域的研究不斷增加以及對個人化醫療的認知不斷增強，預計北美在預測期內將出現最高的成長。

市場規模/估計：以金額的白血病治療市場規模估計（10億美元）

趨勢和預測分析：各細分市場和地區的市場趨勢（2018-2023）和預測（2024-2030）

細分市場分析：按類型、藥物、配銷通路和地區估算的白血病治療市場規模（金額十億美元）

區域分析：北美、歐洲、亞太地區和世界其他地區白血病治療市場細分

成長機會：按類型、藥物、配銷通路和地區分類的白血病治療市場成長機會分析

策略分析：白血病治療市場併購、新產品開發、競爭形勢等

基於波特五力模型的產業競爭實力分析

本報告回答了 11 個關鍵問題：

Q.1. 細分市場中最有前途和高成長的機會是什麼？
Q.2.哪個細分市場將以更快的速度成長？為什麼？
Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
Q.5. 這個市場的商業風險和競爭威脅是什麼？
Q.6.這個市場有哪些新趨勢？為什麼？
Q.7.市場客戶需求有何改變？
Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

宏觀經濟趨勢（2018-2023）與預測（2024-2030）
全球白血病治療市場趨勢（2018-2023）與預測（2024-2030）
全球白血病治療市場：按類型
- 急性淋巴性白血病
- 急性骨髓性白血病
- 慢性淋巴性白血病
- 慢性骨髓性白血病
- 其他
全球白血病治療市場：依藥物分類
- 化療
- 標靶治療/免疫治療
全球白血病治療市場：按配銷通路
- 醫院藥房
- 藥局/零售藥房
- 線上提供者

第4章市場趨勢與預測分析：按地區（2018-2030）

全球白血病治療市場：按地區
北美白血病治療市場
歐洲白血病治療市場
亞太白血病治療市場
其他地區白血病治療市場

第5章競爭分析

產品系列分析
營運整合
波特五力分析

第6章成長機會與策略分析

成長機會分析
- 按類型分類的全球白血病治療市場成長機會
- 全球白血病治療市場藥物成長機會
- 按配銷通路的全球白血病治療市場成長機會
- 全球白血病治療市場按地區成長機會
全球白血病治療市場新趨勢
戰略分析
- 新產品開發
- 擴大全球白血病治療市場的產能
- 全球白血病治療市場的合併、收購與合資企業
- 認證和許可

第7章主要企業概況

Bristol-Myers Squibb
Takeda Pharmaceutical
Lupin
Gilead Sciences
Novartis
Amgen
Teva Pharmaceutical Industries
Abbvie
Pfizer
Sanofi

簡介目錄

Leukemia Therapeutics Trends and Forecast

The future of the global leukemia therapeutics market looks promising with opportunities in the hospital pharmacies, drug store and retail pharmacies, and online provider markets. The global leukemia therapeutics market is expected to reach an estimated $21.46 billion by 2030 with a CAGR of 8.4% from 2024 to 2030. The major drivers for this market are growing incidence of leukemia, increasing need for more effective treatment for lukemia and rising R&D spending in the healthcare industry.

A more than 150-page report is developed to help in your business decisions.

Leukemia Therapeutics by Segment

The study includes a forecast for the global leukemia therapeutics by type, drug, distribution channel, and region.

Leukemia Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Others

Leukemia Therapeutics Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

Chemotherapy
Targeted Therapy and Immunotherapy

Leukemia Therapeutics Market by Distribution channel [Shipment Analysis by Value from 2018 to 2030]:

Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Providers

Leukemia Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Leukemia Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies leukemia therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the leukemia therapeutics companies profiled in this report include-

Bristol-Myers Squibb
Takeda Pharmaceutical
Lupin
Gilead Sciences
Novartis
Amgen
Teva Pharmaceutical Industries
Abbvie
Pfizer
Sanofi

Leukemia Therapeutics Market Insights

Lucintel forecasts that chronic lymphocytic leukemia will remain the largest segment over the forecast period due to increase in product approvals for chronic lymphocytic leukemia and presence of leukemia therapeutics for chronic lymphocytic leukemia.

Within this market, hospital pharmacies will remain the largest segment due to growing public awareness regarding leukemia and its treatment options along with increasing number of people seeking treatment in hospitals.

North America is expected to witness highest growth over the forecast period due to growing research in the field of regenerative medicine for the treatment of leukemia and rising awareness on personalized medicine in the region.

Features of the Global Leukemia Therapeutics Market

Market Size Estimates: Leukemia therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Leukemia therapeutics market size by type, drug, distribution channel, and region in terms of value ($B).

Regional Analysis: Leukemia therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, drugs, distribution channels, and regions for the leukemia therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the leukemia therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the leukemia therapeutics market size?

Answer: The global leukemia therapeutics market is expected to reach an estimated $21.46 billion by 2030.

Q.2 What is the growth forecast for leukemia therapeutics market?

Answer: The global leukemia therapeutics market is expected to grow with a CAGR of 8.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the leukemia therapeutics market?

Answer: The major drivers for this market are growing incidence of leukemia, increasing need for more effective treatment for lukemia and rising R&D spending in the healthcare industry.

Q4. What are the major segments for leukemia therapeutics market?

Answer: The future of the leukemia therapeutics market looks promising with opportunities in the hospital pharmacies, drug store and retail pharmacies, and online provider markets.

Q5. Who are the key leukemia therapeutics market companies?

Answer: Some of the key leukemia therapeutics companies are as follows:

Bristol-Myers Squibb
Takeda Pharmaceutical
Lupin
Gilead Sciences
Novartis
Amgen
Teva Pharmaceutical Industries
Abbvie
Pfizer
Sanofi

Q6. Which leukemia therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that chronic lymphocytic leukemia will remain the largest segment over the forecast period due to increase in product approvals for chronic lymphocytic leukemia and presence of leukemia therapeutics for chronic lymphocytic leukemia.

Q7. In leukemia therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to growing research in the field of regenerative medicine for the treatment of leukemia and rising awareness on personalized medicine in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the leukemia therapeutics market by type (acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia,chronic myeloid leukemia, and others), drug (chemotherapy, and targeted therapy & immunotherapy), distribution channel (hospital pharmacies, drug store and retail pharmacies, and online providers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Leukemia Therapeutics Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Leukemia Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Leukemia Therapeutics Market by Type
- 3.3.1: Acute Lymphocytic Leukemia
- 3.3.2: Acute Myeloid Leukemia
- 3.3.3: Chronic Lymphocytic Leukemia
- 3.3.4: Chronic Myeloid Leukemia
- 3.3.5: Others
3.4: Global Leukemia Therapeutics Market by Drug
- 3.4.1: Chemotherapy
- 3.4.2: Targeted Therapy and Immunotherapy
3.5: Global Leukemia Therapeutics Market by Distribution channel
- 3.5.1: Hospital Pharmacies
- 3.5.2: Drug Store and Retail Pharmacies
- 3.5.3: Online Providers

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Leukemia Therapeutics Market by Region
4.2: North American Leukemia Therapeutics Market
- 4.2.2: North American Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
4.3: European Leukemia Therapeutics Market
- 4.3.1: European Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
- 4.3.2: European Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
4.4: APAC Leukemia Therapeutics Market
- 4.4.1: APAC Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
- 4.4.2: APAC Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
4.5: ROW Leukemia Therapeutics Market
- 4.5.1: ROW Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
- 4.5.2: ROW Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Leukemia Therapeutics Market by Type
- 6.1.2: Growth Opportunities for the Global Leukemia Therapeutics Market by Drug
- 6.1.3: Growth Opportunities for the Global Leukemia Therapeutics Market by Distribution channel
- 6.1.4: Growth Opportunities for the Global Leukemia Therapeutics Market by Region
6.2: Emerging Trends in the Global Leukemia Therapeutics Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Leukemia Therapeutics Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Leukemia Therapeutics Market
- 6.3.4: Certification and Licensing